NAPM, NPA JOIN IN ASKING USTR TO SEEK "BOLAR" EXEMPTION
NAPM, NPA JOIN IN ASKING USTR TO SEEK "BOLAR" EXEMPTION to European Community patent law. In an Oct. 6 statement, the National Association of Pharmaceutical Manufacturers and the National Pharmaceutical Alliance jointly announced their agreement to work together to persuade the U.S. Trade Representative to lobby the European Community for patent law amendments that would allow generic manufacturers to use patented drug products in tests to meet pre-approval regulatory requirements. Now 20-year patent laws enacted by EC countries have not included provisions parallel to the U.S. patent law experimental/regulatory use exemption (under what has been called the "Bolor provision" of the 1984 Waxman/Hatch Act). The experimental/regulatory use exemption permits U.S. generic companies to test their prospective products against brand name drugs before expiration of the reference product's U.S. patent. However, without a similar exemption in EC patent laws, they say they will be unable to obtain bulk from their European suppliers. If the industry is forced to wait for European patent expiry before obtaining raw material for testing, generic competition could be delayed three to six years after brand name products are off patent in the U.S., the associations explain. NAPM has discussed the issue with USTR officials since early spring, and NPA more than doubles the number of companies (to nearly 200) pushing for an amendment. NAPM expects that "the addition of NPA with its 125 member companies will add more impetus to this urgent matter." Last March, Sen. Pryor (D-Ark.) wrote to USTR Ambassador Mickey Kantor urging that he "strongly advise our trading partners of the need for a special exemption in foreign patent laws" ("The Pink Sheet" March 29, T&G-5).
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth